Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/31.CaE0WMJl.js ...

Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Ibex Prostate Detect, an ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company ("Lilly"). This collaboration focuses on ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

By capitalizing on its advantages for business of all sizes, Wisconsin is seeing significant growth in legacy and emerging ...

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...